# RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

> **NCT00819546** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Richard Stone, MD** · enrollment: 29 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** RAD001
- **DRUG:** PKC412

## Key facts

- **NCT ID:** NCT00819546
- **Lead sponsor:** Richard Stone, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00819546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00819546, "RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00819546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*